This week we look at a clinical trial of treatments for tuberculosis, the PanaCEA MAMS-TB study. I’ve been involved with TB on and off since project-managing and statisticizing the original NICE guideline back in the day. I won’t go into detail on TB treatments but the trial compares various combinations of drugs, and there’s a new candidate drug called SQ109 in the mix. The paper is here (I hope it is not paywalled). You can see the Kaplan-Meier plot on page 44. Without going into detail, these are classic formats for clinical trials looking at time-to-event data. As time goes by, people either get recurrence of the disease or disappear out of the trial, and the numbers at risk go down. You want to be in a group whose curve descends less steeply.
But there are different ways of measuring and counting events, so the authors made an interactive web page showing these as a sensitivity analysis. Hooray!
It’s a pity Lancet paid such lip service to it, tucked away as a link in the margin of page 45. Boo!
I found the transitions in the table of patients at risk weird – I guess that’s the d3 transition deciding to move the numbers horizontally and it might be clearer to fade them out, remove them, then put them back from scratch. It’s also clear that Mike Bostock never had to deal with step functions in transition. But otherwise a really nice example of how trials can provide more layers of info.